E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
glioblastoma |
Patienten mit dem ersten oder zweiten Progress eines Glioblastoms nach dem Versagen der Standardtherapie, die eine Radiochemotherapie mit Temozolomid beinhaltet hat und welche außerdem Kandidaten für Re-Bestrahlung sind. |
|
E.1.1.1 | Medical condition in easily understood language |
Patients with glioblastoma at first or second progression who have failed standard treatment that must have included radiochemotherapy with temozolomide and who are a candidate for a reirradiation |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10018337 |
E.1.2 | Term | Glioblastoma multiforme |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10018336 |
E.1.2 | Term | Glioblastoma |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Phase I - Maximal tolerated dose of BIBF1120 in combination reirradiation - Safety and tolerability of BIBF1120 in conjunction with radiotherapy - Pharmacokinetic studies in plasma and cerebrospinal fluid
Phase II Primary objective: - 6 months rate of progression-free survival (PFS6)
|
|
E.2.2 | Secondary objectives of the trial |
Secondary objectives: - Safety and tolerability of BIBF1120 Phase II Secondary objectives: - Safety and tolerability of BIBF1120 - Progression-free survival - Objective response rates (OR) - Duration of response (DR) in responders - Overall survival - Quality of life as determined by EORTC QLQ-C15-PAL and the EORTC brain module QLQ-BN 20 - Cognitive function determined by MMSE/NeuroCoq Fx
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Male and female patients with a recurrence / progression of glioblastoma either not being eligible for tumour resection or having macroscopic residual tumor after resection of the recurrence - Diagnosis of glioblastoma must be proven histologically and progress must be documented by MRI. MRI images must not be older than 2 weeks before first dosing/start of RT - Not more than two prior therapy regimens including one or two resections, one or two chemotherapies (one temozolomidecontaining concomitant to radiotherapy) and one radiotherapy (RT) for the brain tumor - Previous irradiation therapy of the primary tumor with a maximal dose of 60 Gy; at least 8 months since the end of preirradiation - Candidate for reirradiation with recurrent tumor visible on MRIT1 (Gd) and with the largest diameter measuring 1 cm to 5 cm - Informed consent - Age ≥ 18 years, smoking or non-smoking, of any ethnic origin - Karnofsky performance index (KPI) ≥ 60% - Neutrophile counts > 1500/μl / Platelet counts > 80.000/μl / Haemoglobin > 10 g/dl / Serum creatinine < 1.5-fold upper normal range / Bilirubin, AST or ALT < 2,5-fold upper normal range unless attributed to anticonvulsants / Alkaline phosphatase < 2,5-fold upper normal range - Adequate contraception - If on steroids, stable or decreasing treatment with steroids within 5 days before treatment start |
|
E.4 | Principal exclusion criteria |
- More than one RT of brain, prior first radiotherapy with more than 60 Gy - Cumulative total dose on the optical chiasm >54 Gy for 2 Gy/fraction, α/β=2 - Prior treatment with bevacizumab, iodine seeds and/or brachytherapy - Unable to undergo contrast-enhanced MRI - Past medical history of diseases with poor prognosis according to the judgement of the Investigator, e.g. severe coronary heart disease, severe diabetes, immune deficiency, residual deficits after stroke, severe mental retardation - HIV or hepatitis infection - Pregnancy or breast feeding - Treatment within any other clinical trial parallel to the treatment phase of the current study or within 30 days before inclusion - Known coronary artery disease, significant cardiac arrhythmias or severe congestive heart failure (NYHA class III – IV) |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Phase I: Maximal tolerated dose of BIBF1120 in combination with reirradiation
Phase II: Progression free survival |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Phase I: Daily evaluation of dose limiting toxicities Phase II: every 6 weeks |
|
E.5.2 | Secondary end point(s) |
Phase I: safety and tolerability Phase II: response rates, overall survival, quality of life |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Phase I: weekly evaluation Phase II: every 6 weeks / 6 months after randomization |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Yes |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | Yes |
E.7.1.3.1 | Other trial type description |
Pharmacokinetic parameters of BIBF 1120 in plasma and cerebrospinal fluid |
|
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
radiotherapy against radiotherapy with chemotherapy |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 15 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Disease progression, unacceptable toxicity, need to reduce dose of BIBF1120 below 150 mg twice daily, need for another anticancer therapy, non-compliance of the patient, withdrawal of patient’s consent |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |